Acquisitions - Acquisition-Date Fair Value of Consideration Transferred (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2012
ZEVALIN [Member]
Business Acquisition [Line Items]
Cash consideration	$ 25,435
Total liabilities assumed	580
Total purchase consideration	26,015
Allos Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Cash consideration	205,204
Contingent value right
Total purchase consideration	$ 205,204

Amount of cash paid to acquire the entity.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-Subparagraph f(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Name:	us-gaap_BusinessAcquisitionCostOfAcquiredEntityCashPaid
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant